Growth Hormone peptides

17 peptides tagged growth hormone. Each page carries the dosing reference, mechanism, evidence grade and references.

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

  • CJC-1295

    GHRH(1-29) analog carrying a Drug Affinity Complex that binds serum albumin, extending half-life to about a week and sustaining growth hormone and IGF-1 output.

    Evidence: Clinical

  • CJC-1295 + GHRP-2 Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-2 (pralmorelin), 5 mg each; GHRP-2 raised GH and appetite in human studies, and no study has tested the pair.

    Evidence: Preclinical

  • CJC-1295 + GHRP-6 Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-6, 5 mg each; GHRP-6 raised GH in men and synergized with GHRH, and no study has tested this pair.

    Evidence: Preclinical

  • CJC-1295 + Ipamorelin Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin, sold as 10 mg (5 mg each); the two act on separate GH-releasing receptors, and no study has tested the pair.

    Evidence: Preclinical

  • CJC-1295 no DAC (Mod GRF 1-29)

    Tetrasubstituted GHRH(1-29) analog ([D-Ala2, Gln8, Ala15, Leu27]), the peptide part of CJC-1295 without its albumin-binding linker; no published study of this exact peptide, each substitution characterized separately.

    Evidence: Preclinical

  • Fragment 176-191 + Mod GRF + Ipamorelin

    Vial blend of a GH fragment sold as 176-191, Mod GRF 1-29 and ipamorelin (12 mg: 6/3/3 mg); fat-loss claims rest on rodent data, and no study has tested the mix.

    Evidence: Preclinical

  • Ghrelin

    28-amino-acid stomach hormone and the endogenous GHS-R1a ligand; drives hunger, GH release and gastric motility in human infusion studies.

    Evidence: Clinical

  • GHRH

    Native hypothalamic hormone (somatorelin, GHRH 1-44) that triggers GH release from pituitary somatotrophs; used clinically as a diagnostic GH-stimulation agent.

    Evidence: Clinical

  • GHRP-2

    Synthetic hexapeptide ghrelin-receptor agonist (pralmorelin, KP-102) that raised GH and food intake 36% in healthy men (n=7); approved in Japan as a single-dose GH-deficiency diagnostic (GHRP Kaken 100).

    Evidence: Clinical

  • GHRP-6

    First synthetic GH-releasing hexapeptide (Bowers 1984); raised GH dose-dependently and synergized with GHRH in normal men (n=18). Appetite and gut-motility effects are documented in rodents.

    Evidence: Clinical

  • Hexarelin

    Highly potent synthetic hexapeptide GH secretagogue that also showed direct cardioprotective effects in animal work; desensitizes the GH axis with continuous use.

    Evidence: Clinical

  • Ipamorelin

    Pentapeptide ghrelin-receptor agonist that released GH without raising ACTH or cortisol in swine (Raun 1998); human data are a PK study (n=40) and one negative phase 2 trial in postoperative ileus (n=114).

    Evidence: Preclinical

  • MK-677

    Ibutamoren, an orally active non-peptide ghrelin receptor agonist that raises GH and IGF-1 in human trials; studied for lean mass, bone density, and sleep quality.

    Evidence: Clinical

  • Sermorelin

    Synthetic GHRH(1-29) analog (Geref; FDA-approved 1997 for pediatric GH deficiency, withdrawn 2008 for commercial reasons) that restored GH and IGF-1 to young-adult levels in older men (n=10).

    Evidence: Clinical

  • Sermorelin + Ipamorelin Blend

    Vial blend of sermorelin (GHRH 1-29) and ipamorelin, 5 mg each; sermorelin raised GH and IGF-1 in older men, ipamorelin's only RCT was negative, and no study has tested the pair.

    Evidence: Preclinical

  • Tesamorelin

    Synthetic GHRH(1-44) analog, FDA-approved 2010 (Egrifta) for excess abdominal fat in HIV lipodystrophy; cut visceral fat about 15% vs placebo over 26 weeks in two phase 3 RCTs (n=806).

    Evidence: Clinical

  • Tesamorelin + Ipamorelin Blend

    Vial blend of tesamorelin and ipamorelin (vendors sell 6/2 mg and 10/3 mg); tesamorelin cut visceral fat in HIV phase 3 trials, and no study has tested the pair.

    Evidence: Preclinical

Other categories